The role of immunotherapy in urothelial cancers

Hélène Houssiau MD1, Emmanuel Seront MD PhD1 Published in the journal : March 2022 Category : Oncologie médicale

Immune checkpoint inhibitors (ICIs) have significantly improved the outcome of patients with urothelial cancer. Several ICIs are currently approved in Belgium, such as pembrolizumab, avelumab, atezolizumab, and nivolumab. These ICIs were first evaluated in the metastatic setting, following failure of platinum-based chemotherapy. New strategies have been evaluated over the last years, including ICI plus chemotherapy, ICI monotherapy, or maintenance therapy, referring to introducing ICI after chemotherapy without waiting for disease progression. Other clinical trials are currently ongoing, which evaluate ICI in perioperative setting, be it neoadjuvant or adjuvant. This paper sought to review the current knowledge concerning ICIs in urothelial carcinoma, in addition to the new indications of these agents in this specific domain.

Read more

ONCOVID, or how not to harm

Alice Kalantari, Jean-Pascal Machiels, Cédric Van Marcke Published in the journal : May 2020 Category : Oncologie médicale

The management of oncology patients during a pandemic is a challenge on several levels. We have never faced before a pandemic of this magnitude, especially in the era of advanced medicine that uses many immunosuppressive or immunomodulating drugs.

Read more